Form 4 for EDSA Edesa Biotech, Inc.
Accepted 2026-07-02 17:05:48 ET · period of report 2026-07-02 · accession 0001171843-26-004451 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-02 17:05 | 2026-07-02 | EDSA | Nijhawan Pardeep | CEO, Dir, 10% | A - Grant | $0.00 | +3,378 | 888.1K | +0.4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-07-02 | A | A | 3,378 | $0.00 | 888,062 | D | — | — | (F1) Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. (F1) Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. |